SEC Filing Summary: Predictive Oncology Inc. (POAI)
Business Context and Reporting Period
This Form 8-K was filed on July 23, 2025, by Predictive Oncology Inc. (POAI), a Delaware corporation listed on the Nasdaq Capital Market. The report addresses the outcome of a hearing regarding the Company's compliance with Nasdaq listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status rather than financial performance metrics.
Material Changes and Events
- Delisting Determination: On June 9, 2025, Nasdaq notified the Company of a determination to delist its securities due to non-compliance with the minimum $2,500,000 stockholders' equity requirement (Rule 5550(b)(1)).
- Bid Price Deficiency: On July 8, 2025, the Company received notice of non-compliance with the minimum bid price requirement (Rule 5550(a)(2)) after the stock closed below $1.00 per share for 30 consecutive business days.
- Hearing Outcome: Following a hearing on July 17, 2025, the Nasdaq Hearings Panel granted the Company's request for continued listing.
Guidance, Outlook, and Risks
The Company has been granted an extension through December 8, 2025, to demonstrate compliance with all continued listing requirements, including both the Stockholders' Equity and Bid Price requirements. Management is pursuing actions to satisfy these terms; however, the filing explicitly states there can be no assurance that the Company will be able to do so. Failure to regain compliance by the deadline may result in delisting from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the Company's current stockholders' equity balance to assess progress toward the $2,500,000 threshold.
- Monitor the daily closing bid price of POAI common stock to ensure it remains above $1.00 per share.
- Review subsequent filings for details on specific capital raising or restructuring actions taken to meet the December 8, 2025 deadline.
- Confirm the Company's status on the Nasdaq Capital Market to ensure no further suspension notices have been issued.